Wall Street brokerages expect EQRx, Inc. (NASDAQ:EQRX – Get Rating) to announce earnings of ($0.25) per share for the current quarter, according to Zacks. Zero analysts have made estimates for EQRx’s earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.19). The business is scheduled to issue its next earnings report before the market opens on Monday, January 1st.
According to Zacks, analysts expect that EQRx will report full-year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($0.83). For the next year, analysts expect that the business will post earnings of ($1.12) per share, with EPS estimates ranging from ($1.34) to ($0.89). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for EQRx.
EQRX has been the topic of a number of research reports. Jefferies Financial Group began coverage on EQRx in a research report on Friday, March 18th. They set a “buy” rating and a $5.60 target price on the stock. Cowen began coverage on EQRx in a research report on Friday, April 22nd. They issued an “outperform” rating for the company. Finally, Cowen began coverage on EQRx in a research note on Friday, April 22nd. They issued an “outperform” rating on the stock.
Shares of EQRX opened at $3.72 on Friday. EQRx has a 52 week low of $2.63 and a 52 week high of $11.10. The firm has a fifty day moving average price of $4.13.
EQRx Company Profile (Get Rating)
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.